Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.

Tan SH, Leong WZ, Ngoc PCT, Tan TK, Bertulfo FC, Lim MC, An O, Li Z, Yeoh AEJ, Fullwood MJ, Tenen DG, Sanda T.

Blood. 2019 Jul 18;134(3):239-251. doi: 10.1182/blood.2018874503. Epub 2019 May 10.

PMID:
31076442
2.

Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children.

Qian M, Zhao X, Devidas M, Yang W, Gocho Y, Smith C, Gastier-Foster JM, Li Y, Xu H, Zhang S, Jeha S, Zhai X, Sanda T, Winter SS, Dunsmore KP, Raetz EA, Carroll WL, Winick NJ, Rabin KR, Zweidler-Mckay PA, Wood B, Pui CH, Evans WE, Hunger SP, Mullighan CG, Relling MV, Loh ML, Yang JJ.

J Natl Cancer Inst. 2019 Apr 2. pii: djz043. doi: 10.1093/jnci/djz043. [Epub ahead of print]

PMID:
30938820
3.

Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.

Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang CY, Conradie F, Dongo JP, Heldal E, Jensen P, Nyengele JPK, Koura KG, Kumar AMV, Lin Y, Mlilo N, Nakanwagi-Mukwaya A, Ncube RT, Nyinoburyo R, Oo NL, Patel LN, Piubello A, Rusen ID, Sanda T, Satyanarayana S, Syed I, Thu AS, Tonsing J, Trébucq A, Zamora V, Zishiri C, Hinderaker SG, Aït-Khaled N, Roggi A, Caminero Luna J, Graham SM, Dlodlo RA, Fujiwara PI.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251. doi: 10.5588/ijtld.18.0207.

PMID:
30808459
4.

The transcription factor SP3 drives TNF-α expression in response to Smac mimetics.

Beug ST, Cheung HH, Sanda T, St-Jean M, Beauregard CE, Mamady H, Baird SD, LaCasse EC, Korneluk RG.

Sci Signal. 2019 Jan 29;12(566). pii: eaat9563. doi: 10.1126/scisignal.aat9563.

PMID:
30696705
5.

[A Case of Small Intestinal Neuroendocrine Tumor Detected One Year after Resection of Liver Metastasis].

Fujimura Y, Tabata M, Sakamoto T, Maeda K, Ohsawa I, Kato K, Iwata M, Sanda T.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2180-2182. Japanese.

PMID:
30692324
6.

Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.

Tan TK, Zhang C, Sanda T.

Int J Hematol. 2019 Jan;109(1):5-17. doi: 10.1007/s12185-018-2518-z. Epub 2018 Aug 25. Review.

PMID:
30145780
7.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2019 Mar;33(3):696-709. doi: 10.1038/s41375-018-0239-1. Epub 2018 Aug 21.

PMID:
30131584
8.

[Understanding of molecular pathogenesis of T-cell leukemia by super-enhancer profiling].

Sanda T.

Rinsho Ketsueki. 2018;59(7):899-908. doi: 10.11406/rinketsu.59.899. Review. Japanese.

PMID:
30078801
9.

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.

Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S.

Haematologica. 2018 Dec;103(12):2059-2068. doi: 10.3324/haematol.2018.191395. Epub 2018 Aug 3.

10.

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2018 Jul 18;9:16231. doi: 10.1038/ncomms16231.

11.

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, Rahman S, Leon TE, Kuang YY, Zimmerman MW, Blonquist T, Gjini E, Gutierrez A, Tang Q, Garcia-Perez L, Pike-Overzet K, Anders L, Berezovskaya A, Zhou Y, Zon LI, Neuberg D, Fielding AK, Staal FJT, Langenau DM, Sanda T, Young RA, Look AT.

J Exp Med. 2018 Jul 2;215(7):1929-1945. doi: 10.1084/jem.20170484. Epub 2018 Jun 25.

12.

Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia.

Wong RWJ, Ishida T, Sanda T.

Molecules. 2018 May 2;23(5). pii: E1057. doi: 10.3390/molecules23051057. Review.

13.

Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.

Ngoc PCT, Tan SH, Tan TK, Chan MM, Li Z, Yeoh AEJ, Tenen DG, Sanda T.

Leukemia. 2018 Oct;32(10):2138-2151. doi: 10.1038/s41375-018-0110-4. Epub 2018 Mar 26.

PMID:
29654272
14.

[A Resected Case of UR-LA Pancreatic Tail Cancer with Aortic Invasion after Chemoradiotherapy].

Fujimura Y, Tabata M, Sakamoto T, Maeda K, Ohsawa I, Kato K, Iwata M, Sanda T.

Gan To Kagaku Ryoho. 2018 Jan;45(1):151-153. Japanese.

PMID:
29362338
15.

ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.

Leong WZ, Tan SH, Ngoc PCT, Amanda S, Yam AWY, Liau WS, Gong Z, Lawton LN, Tenen DG, Sanda T.

Genes Dev. 2017 Dec 1;31(23-24):2343-2360. doi: 10.1101/gad.302646.117. Epub 2018 Jan 11.

16.

Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia.

Tan SH, Bertulfo FC, Sanda T.

Front Oncol. 2017 Sep 25;7:218. doi: 10.3389/fonc.2017.00218. eCollection 2017. Review.

17.

RUNX1 in T-ALL: tumor suppressive or oncogenic?

Sanda T.

Blood. 2017 Oct 12;130(15):1686-1688. doi: 10.1182/blood-2017-08-802181. No abstract available.

18.

Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.

Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, Ishida T, Sanda T.

Blood. 2017 Nov 23;130(21):2326-2338. doi: 10.1182/blood-2017-06-792184. Epub 2017 Oct 4.

19.

TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.

Sanda T, Leong WZ.

Exp Hematol. 2017 Sep;53:7-15. doi: 10.1016/j.exphem.2017.06.001. Epub 2017 Jun 24. Review.

PMID:
28652130
20.

Roles of the RUNX1 Enhancer in Normal Hematopoiesis and Leukemogenesis.

Liau WS, Ngoc PC, Sanda T.

Adv Exp Med Biol. 2017;962:139-147. doi: 10.1007/978-981-10-3233-2_10. Review.

PMID:
28299656
21.

Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.

Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwood JR, Tiv H, Sanda T, Weinstock DM, Look AT.

Br J Haematol. 2017 Apr;177(2):271-282. doi: 10.1111/bjh.14563. Epub 2017 Mar 14.

22.

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR, Young RA, Look AT.

Leukemia. 2017 Oct;31(10):2057-2064. doi: 10.1038/leu.2017.75. Epub 2017 Mar 6.

23.

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma.

Beug ST, Beauregard CE, Healy C, Sanda T, St-Jean M, Chabot J, Walker DE, Mohan A, Earl N, Lun X, Senger DL, Robbins SM, Staeheli P, Forsyth PA, Alain T, LaCasse EC, Korneluk RG.

Nat Commun. 2017 Feb 15;8. doi: 10.1038/ncomms14278. Erratum in: Nat Commun. 2018 Jul 18;9:16231.

24.

Ontogenetic change of body color patterns in laboratory-raised juveniles of six terrestrial hermit crab species.

Hamasaki K, Tsuru T, Sanda T, Fujikawa S, Dan S, Kitada S.

Zootaxa. 2017 Jan 30;4226(4):zootaxa.4226.4.5. doi: 10.11646/zootaxa.4226.4.5.

PMID:
28187605
25.

[A Case of Primary Peritoneal Cancer Successfully Treated with Debulking Surgery and Postoperative Chemotherapy].

Maeda K, Tabata M, Moriyama T, Sakamoto T, Fujimura Y, Ohsawa I, Kato K, Iwata M, Sanda T.

Gan To Kagaku Ryoho. 2016 Nov;43(12):2115-2117. Japanese.

PMID:
28133240
26.

Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.

Liau WS, Tan SH, Ngoc PCT, Wang CQ, Tergaonkar V, Feng H, Gong Z, Osato M, Look AT, Sanda T.

Leukemia. 2017 Aug;31(8):1798-1807. doi: 10.1038/leu.2016.392. Epub 2016 Dec 28.

27.

Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

J Cancer. 2016 Jun 3;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016.

28.

The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.

Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H.

Leukemia. 2016 Jun;30(6):1365-74. doi: 10.1038/leu.2016.26. Epub 2016 Feb 15.

29.

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.

Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC.

Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258.

30.

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.

Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Weinstock DM, Look AT.

Leukemia. 2016 Jan;30(1):219-28. doi: 10.1038/leu.2015.222. Epub 2015 Aug 12.

31.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD.

Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23.

32.

TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia.

Tan SH, Yam AW, Lawton LN, Wong RW, Young RA, Look AT, Sanda T.

Leukemia. 2016 Apr;30(4):959-62. doi: 10.1038/leu.2015.195. Epub 2015 Jul 23. No abstract available.

33.

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT.

Science. 2014 Dec 12;346(6215):1373-7. doi: 10.1126/science.1259037. Epub 2014 Nov 13.

34.

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.

Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.

Oncotarget. 2014 Sep 30;5(18):8737-49.

35.

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.

Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS.

Nature. 2014 Jul 31;511(7511):616-20. doi: 10.1038/nature13393. Epub 2014 Jun 22.

36.

Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.

Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N.

Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041. Epub 2014 Jul 3.

37.

RUNX1 point mutations potentially identify a subset of early immature T-cell acute lymphoblastic leukaemia that may originate from differentiated T-cells.

Mok MM, Du L, Wang CQ, Tergaonkar V, Liu TC, Yin Kham SK, Sanda T, Yeoh AE, Osato M.

Gene. 2014 Jul 15;545(1):111-6. doi: 10.1016/j.gene.2014.04.074. Epub 2014 May 2.

PMID:
24792891
38.

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H.

Leukemia. 2014 May;28(5):1145-8. doi: 10.1038/leu.2013.377. Epub 2013 Dec 17. No abstract available.

39.

The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.

Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, von Boehmer H, Young RA, Look AT.

J Exp Med. 2013 Jul 29;210(8):1545-57. doi: 10.1084/jem.20122516. Epub 2013 Jul 15.

40.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS.

ACS Chem Biol. 2013 Jul 19;8(7):1423-8. doi: 10.1021/cb4000629. Epub 2013 Apr 26.

PMID:
23594111
41.

TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT.

Cancer Discov. 2013 May;3(5):564-77. doi: 10.1158/2159-8290.CD-12-0504. Epub 2013 Mar 7.

42.

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A.

Br J Haematol. 2013 Apr;161(1):117-27. doi: 10.1111/bjh.12231. Epub 2013 Feb 4.

43.

The requirement for cyclin D function in tumor maintenance.

Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, Sicinski P.

Cancer Cell. 2012 Oct 16;22(4):438-51. doi: 10.1016/j.ccr.2012.09.015.

44.

Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.

Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, Ma W, Tatarek J, Ahn Y, Kelliher MA, Jamieson CH, Staudt LM, Young RA, Look AT.

Cancer Cell. 2012 Aug 14;22(2):209-21. doi: 10.1016/j.ccr.2012.06.007.

45.

PIDD death-domain phosphorylation by ATM controls prodeath versus prosurvival PIDDosome signaling.

Ando K, Kernan JL, Liu PH, Sanda T, Logette E, Tschopp J, Look AT, Wang J, Bouchier-Hayes L, Sidi S.

Mol Cell. 2012 Sep 14;47(5):681-93. doi: 10.1016/j.molcel.2012.06.024. Epub 2012 Jul 30.

46.

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.

Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, Look AT.

Leukemia. 2013 Jan;27(1):66-74. doi: 10.1038/leu.2012.219. Epub 2012 Jul 31.

47.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE.

Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001.

48.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

49.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N.

Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3.

50.

Deletion of the PHO13 gene in Saccharomyces cerevisiae improves ethanol production from lignocellulosic hydrolysate in the presence of acetic and formic acids, and furfural.

Fujitomi K, Sanda T, Hasunuma T, Kondo A.

Bioresour Technol. 2012 May;111:161-6. doi: 10.1016/j.biortech.2012.01.161. Epub 2012 Feb 6.

PMID:
22357292

Supplemental Content

Support Center